(Psych Central News) In one of the first instances of targeted drug design in psychiatric treatment, researchers have found an experimental agent that shows promise in addressing working memory impairments that occur in schizophrenia. The University of Pittsburgh study breaks new ground in the strategy used to develop new pharmacological treatments for schizophrenia, explained David Lewis, M.D., [...]

Read the full article...

From Psych Central News.